Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit
Translate Bio (Nasdaq: TBIO) announced that CEO Ronald Renaud will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 10:30 a.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Translate Bio (Nasdaq: TBIO) announced that CEO Ronald Renaud will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 10:30 a.m. EST. A live webcast will be available on the company’s website, and a replay will be archived for 30 days post-event.
Translate Bio focuses on developing mRNA therapeutics for treating diseases like cystic fibrosis and also collaborates with Sanofi Pasteur on mRNA vaccines.
Details
News Market Reaction – TBIO
The recorded move for TBIO in the trading session of this news was +6.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021 at 10:30 a.m. EST.
A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at https://investors.translate.bio/investors/news-and-events. A replay of the webcasts will be archived on the Translate Bio’s website for 30 days following the presentation.
About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.
Contacts for Translate Bio
| Investor | Media |
| Teri Dahlman | Maura Gavaghan |
| tdahlman@translate.bio | mgavaghan@translate.bio |
| 617-817-8655 | 617-233-1154 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.